Net worth: 41 M $ as of 30/05/2026
Richard Francis is President, Chief Executive Officer & Director at Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. since 2023.
Mr. Francis is Director at Mettler-Toledo (Schweiz) GmbH since 2016 and Director at Purespring Therapeutics Ltd. since 2021.
Former roles include Chief Executive Officer & Division Head at Sandoz International GmbH from 2014 to 2019, Chief Executive Officer at Forcefield Therapeutics Ltd., Independent Director at Mettler-Toledo International, Inc. from 2016 to 2025, and Senior Vice President at Biogen, Inc. from 2006 to 2014.
Education includes an undergraduate degree from Manchester Metropolitan University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 04/06/2026 | 1,177,529 ( 0.1% ) | 41 M $ | 30/05/2026 |
| Companies | Position | Start |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Chief Executive Officer | 31/12/2022 |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for the treatment of kidney diseases | Director/Board Member | 31/12/2022 |
Mettler-Toledo (Schweiz) GmbH
 Mettler-Toledo (Schweiz) GmbH Industrial MachineryProducer Manufacturing Makes weighing equipment | Director/Board Member | 30/04/2016 |
Teva Pharmaceuticals USA, Inc.
 Teva Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Manufacture and marketing generic pharmaceuticals | Chief Executive Officer | 31/12/2022 |
| Companies | Position | End |
|---|---|---|
| METTLER-TOLEDO INTERNATIONAL, INC. | Director/Board Member | 30/04/2025 |
Sandoz International GmbH
 Sandoz International GmbH Pharmaceuticals: GenericHealth Technology Develops and manufactures generic pharmaceuticals | Chief Executive Officer | 30/03/2019 |
| BIOGEN INC. | Corporate Officer/Principal | 31/12/2013 |
Forcefield Therapeutics Ltd.
 Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 9 |
|---|---|
Teva Pharmaceutical Industries Ltd.
 Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Mettler-Toledo International, Inc.
 Mettler-Toledo International, Inc. Medical SpecialtiesHealth Technology Manufactures and supplies precision instruments | Health Technology |
Sandoz International GmbH
Sandoz International GmbH Pharmaceuticals: GenericHealth Technology Develops and manufactures generic pharmaceuticals | Health Technology |
Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Manufacture and marketing generic pharmaceuticals | Health Technology |
Manchester Metropolitan University
 Manchester Metropolitan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mettler-Toledo (Schweiz) GmbH
Mettler-Toledo (Schweiz) GmbH Industrial MachineryProducer Manufacturing Makes weighing equipment | Producer Manufacturing |
Purespring Therapeutics Ltd.
Purespring Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for the treatment of kidney diseases | Health Technology |
Forcefield Therapeutics Ltd.
Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
